Home » Authors » Nuala Moran

Articles by Nuala Moran

Chiron Plans To Pay £542 Million In Cash To Acquire PowderJect

May 21, 2003

LONDON - Chiron Corp. plans to acquire PowderJect Pharmaceuticals plc in an agreed-to cash offer valuing the vaccines manufacturer at £542 million (US$878 million). (BioWorld International)

MedPharma Postpones IPO As Markets Remain Resistant

May 21, 2003

CAT Cuts Staff As Part Of Plan To Concentrate On Development

May 21, 2003

Chiron Plans To Pay £542 Million In Cash To Acquire PowderJect

May 21, 2003

LONDON - Chiron Corp. plans to acquire PowderJect Pharmaceuticals plc in an agreed-to cash offer valuing the vaccines manufacturer at £542 million (US$878 million). (BioWorld International)

CAT Cuts Staff As Part Of Plan To Concentrate On Development

May 21, 2003

MedPharma Postpones IPO As Markets Remain Resistant

May 21, 2003

Acambis Benefits From U.S. Consolidation Of Contracts

May 14, 2003

UK Industry Riding Out Downturn, Surviving Till Sector Turns Around

May 14, 2003

QLT, Xenova Suffer Setback As Pivotal Tariquidar Trial Stopped

May 14, 2003

QLT, Xenova Suffer Setback As Pivotal Tariquidar Trial Stopped

May 14, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.